Business Description
Aker BioMarine ASA
ISIN : NO0010886625
Share Class Description:
OSL:AKBM: Ordinary SharesTotal Employee Number:
244Compare
Compare
Traded in other countries / regions
AKBM.NorwayAKBMo.Sweden1PG.Germany IPO Date
2020-07-06Description
Aker BioMarine ASA is a supplier of krill-derived products, with a fully owned supply chain. The operations of the company span from harvesting krill in Antarctica with vessels owned by the company including distribution from Uruguay, and further processing of the krill into oil products in the United States. The segments of the company include Human Health Ingredients, Consumer Health Products, and Emerging Businesses. The company generates the majority of its revenue from the Human Health Ingredients segment, which includes Superba, Lysoveta, PL+ Algae, and the company's Houston manufacturing plant. The segment sells B2B krill oil supplements to nutritional brands for humans around the world.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.51 | |||||
Debt-to-EBITDA | 10.19 | |||||
Interest Coverage | 0.65 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.71 | |||||
Beneish M-Score | -3.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7 | |||||
3-Year EBITDA Growth Rate | -25.7 | |||||
3-Year FCF Growth Rate | 45.5 | |||||
3-Year Book Growth Rate | -27 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.49 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.92 | |||||
9-Day RSI | 68.91 | |||||
14-Day RSI | 65.13 | |||||
3-1 Month Momentum % | -2.79 | |||||
6-1 Month Momentum % | 1.24 | |||||
12-1 Month Momentum % | 27.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.6 | |||||
Quick Ratio | 1.03 | |||||
Cash Ratio | 0.25 | |||||
Days Inventory | 325.72 | |||||
Days Sales Outstanding | 77.09 | |||||
Days Payable | 130.71 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45 | |||||
Operating Margin % | 6.58 | |||||
Net Margin % | -5.82 | |||||
EBITDA Margin % | 8.62 | |||||
FCF Margin % | -6.87 | |||||
OCF Margin % | -2.31 | |||||
ROE % | -9.16 | |||||
ROA % | -3.36 | |||||
ROIC % | 4.52 | |||||
3-Year ROIIC % | 0.6 | |||||
ROC (Joel Greenblatt) % | 7.04 | |||||
ROCE % | 4.14 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 438.02 | |||||
PS Ratio | 4.11 | |||||
PB Ratio | 7.34 | |||||
Price-to-Tangible-Book | 55.61 | |||||
EV-to-EBIT | 87.81 | |||||
EV-to-Forward-EBIT | 16.54 | |||||
EV-to-EBITDA | 58.75 | |||||
EV-to-Forward-EBITDA | 20.73 | |||||
EV-to-Revenue | 5.07 | |||||
EV-to-Forward-Revenue | 3.98 | |||||
EV-to-FCF | -70.92 | |||||
Price-to-GF-Value | 1.46 | |||||
Earnings Yield (Greenblatt) % | 1.14 | |||||
FCF Yield % | -1.6 | |||||
Forward Rate of Return (Yacktman) % | -16.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aker BioMarine ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 2,235.9 | ||
| EPS (TTM) (kr) | -1.564 | ||
| Beta | 0.3996 | ||
| 3-Year Sharpe Ratio | 0.92 | ||
| 3-Year Sortino Ratio | 1.33 | ||
| Volatility % | 28.78 | ||
| 14-Day RSI | 65.13 | ||
| 14-Day ATR (kr) | 2.993026 | ||
| 20-Day SMA (kr) | 102.76 | ||
| 12-1 Month Momentum % | 27.58 | ||
| 52-Week Range (kr) | 76 - 118 | ||
| Shares Outstanding (Mil) | 87.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aker BioMarine ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aker BioMarine ASA Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-29 | In 86 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 86 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-10 09:00 | 100.00 (+4.06%) | ||
| Second quarter earnings results for 2026 | 2026-07-10 07:00 | 100.00 (+4.06%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 08:30 | 98.40 (+2.93%) | ||
| First quarter earnings results for 2026 | 2026-04-30 07:00 | 98.40 (+2.93%) | ||
| General meeting for 2026 | 2026-04-28 13:00 | 100.20 (-0.79%) | ||
| Annual report for 2025 | 2026-03-26 | 105.20 (+2.73%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-12 09:00 | 96.50 (+1.58%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 07:00 | 96.50 (+1.58%) |
Show
Entries
Aker BioMarine ASA Frequently Asked Questions
What is Aker BioMarine ASA(OSL:AKBM)'s stock price today?
The current price of OSL:AKBM is kr109.00. The 52 week high of OSL:AKBM is kr118.00 and 52 week low is kr76.00.
When is next earnings date of Aker BioMarine ASA(OSL:AKBM)?
The next earnings date of Aker BioMarine ASA(OSL:AKBM) is 2026-10-29.
Does Aker BioMarine ASA(OSL:AKBM) pay dividends? If so, how much?
Aker BioMarine ASA(OSL:AKBM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Aker BioMarine ASA
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers